
Opinion|Videos|February 25, 2025
Living With PNH: Long-Term Management and Caregiver Support
Author(s)David Dingli, MD, PhD, Brandi Lewis
Panelists discuss how they maintain treatment adherence through digital health apps, calendar reminders, and symptom journals while working closely with their care teams to address uncertainties and make informed decisions about therapy adjustments, with crucial support from caregivers who help track appointments and provide emotional encouragement throughout their chronic care journey.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you stay organized with your treatments, appointments, and symptom tracking?
- Have there been times when you felt uncertain about your care plan, and how did your team address that?
- How do you help patients adjust to the idea of paroxysmal nocturnal hemoglobinuria (PNH) as a chronic condition requiring lifelong management?
- What signs indicate that a therapy change may be needed, and how do you guide patients through that transition?
- What role do caregivers play in the patient’s care journey, and what advice would you give to other patients about involving loved ones in their care?
- How do you help patients stay hopeful when treatment adjustments are necessary or when challenges arise?
This program was made possible with support from Novartis Pharmaceuticals.
Advertisement
Related to this article

At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.

At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.

At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.

Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.

Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.

At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5

